In addition, RAS blockade by using ACE inhibitors or Ang II receptor blockers can downregulate TLR4 expression, resulting in decreasing the expression of proinflammatory cytokines and inhibiting the NF-κB activation as well as slowing the development of DN. The gene discussed is NFKB1; the disease is liver dysplastic nodule.